NONO
NoNO Inc. is a biotechnology company dedicated to developing innovative neurotherapeutics for stroke and other neurological disorders. With a focus on protecting the brain against stroke and enhancing recovery, the company leverages its core science of PSD-95 inhibition to offer opportunities for a better life to stroke survivors and patients with neurological conditions. Their pipeline includes promising compounds like nerinetide, NoNO-42, and NoNO-SC, which are in various stages of clinical development to address unmet medical needs in neurology.
Industries
Nr. of Employees
small (1-50)
NONO
479A Wellington Street West, Toronto, Ontario, Canada M5V 1E7
Patents
Products
Intravenous PSD-95 inhibitor peptide for acute ischemic stroke
A blood–brain barrier-penetrant peptide developed for single IV administration in acute ischemic stroke to reduce infarct volume, mortality and improve functional outcomes when administered within a defined therapeutic window.
Autoinjector-compatible PSD-95 inhibitor formulation for early administration
A formulation designed for autoinjector delivery to enable administration by caregivers or paramedics in pre-hospital or home settings to broaden early access to neuroprotection.
Subcutaneous long-acting PSD-95 inhibitor for subacute and chronic neurological conditions
A subcutaneously administered PSD-95 inhibitor formulation with rapid onset and prolonged action intended to support treatment of subacute recovery and chronic neurological conditions outside acute hospital settings.
Intravenous PSD-95 inhibitor peptide for acute ischemic stroke
A blood–brain barrier-penetrant peptide developed for single IV administration in acute ischemic stroke to reduce infarct volume, mortality and improve functional outcomes when administered within a defined therapeutic window.
Autoinjector-compatible PSD-95 inhibitor formulation for early administration
A formulation designed for autoinjector delivery to enable administration by caregivers or paramedics in pre-hospital or home settings to broaden early access to neuroprotection.
Subcutaneous long-acting PSD-95 inhibitor for subacute and chronic neurological conditions
A subcutaneously administered PSD-95 inhibitor formulation with rapid onset and prolonged action intended to support treatment of subacute recovery and chronic neurological conditions outside acute hospital settings.
Services
End-to-end clinical development services including protocol design, multicentre trial execution, investigator coordination, and outcomes analysis for acute CNS indications.
Global regulatory strategy development, CTD preparation and interactions with regulatory authorities to support clinical development and registration.
CMC project planning, coordination with CMOs and analytical laboratories, oversight of stability and release testing, and clinical supply logistics.
End-to-end clinical development services including protocol design, multicentre trial execution, investigator coordination, and outcomes analysis for acute CNS indications.
Global regulatory strategy development, CTD preparation and interactions with regulatory authorities to support clinical development and registration.
CMC project planning, coordination with CMOs and analytical laboratories, oversight of stability and release testing, and clinical supply logistics.
Expertise Areas
- Clinical trial management (Phase 1–3)
- Peptide therapeutics for central nervous system disorders
- Neuroprotection and neurorestoration
- Translational preclinical modelling
Key Technologies
- Peptide-based therapeutics
- PSD-95 inhibition mechanism
- Protease-resistant peptide design
- Blood–brain barrier-penetrant molecules
News & Updates
NoNO Inc. will present results from their latest studies at the World Stroke Congress in Toronto, Canada, October 10-12, 2023.
Coverage of NoNO Inc.'s significant results in stroke phase-III trial.
An article highlighting the promising results of NoNO Inc.'s stroke drug.
NoNO Inc. announced the first participant in its Phase 1 trial evaluating NoNO-42.
NoNO Inc. will present results from their latest studies at the World Stroke Congress in Toronto, Canada, October 10-12, 2023.
Coverage of NoNO Inc.'s significant results in stroke phase-III trial.
An article highlighting the promising results of NoNO Inc.'s stroke drug.
NoNO Inc. announced the first participant in its Phase 1 trial evaluating NoNO-42.